Literature DB >> 3164271

Phase II study of a 21-day continuous infusion schedule with epirubicin in metastatic colorectal cancer.

J Greidanus1, P H Willemse, D T Sleijfer, N H Mulder, R C Verschueren, R Nieweg, E G de Vries.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3164271     DOI： 10.1016/0277-5379(88)90321-5

Source DB:  PubMed          Journal:  Eur J Cancer Clin Oncol        ISSN： 0277-5379


× No keyword cloud information.
  4 in total

1.  Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags.

Authors:  T Dine; J C Cazin; B Gressier; M Luyckx; C Brunet; M Cazin; F Goudaliez; M L Mallevais; I Toraub
Journal:  Pharm Weekbl Sci       Date:  1992-12-11

Review 2.  Continuous infusion of low-dose doxorubicin, epirubicin and mitoxantrone in cancer chemotherapy: a review.

Authors:  J Greidanus; P H Willemse; D R Uges; E T Oremus; Z J De Langen; E G De Vries
Journal:  Pharm Weekbl Sci       Date:  1988-12-09

Review 3.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

4.  Delivery of epirubicin via slow infusion as a strategy to mitigate chemotherapy-induced cardiotoxicity.

Authors:  Fang Yang; Qiao Lei; Lu Li; Jian Chang He; Jiajia Zeng; Chunxiang Luo; Sai-Ching Jim Yeung; Runxiang Yang
Journal:  PLoS One       Date:  2017-11-13       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.